Cargando…

Beyond D’Amico risk classes for predicting recurrence after external beam radiotherapy for prostate cancer: the Candiolo classifier

BACKGROUND: The aim of this work is to develop an algorithm to predict recurrence in prostate cancer patients treated with radical radiotherapy, getting up to a prognostic power higher than traditional D’Amico risk classification. METHODS: Two thousand four hundred ninety-three men belonging to the...

Descripción completa

Detalles Bibliográficos
Autores principales: Gabriele, Domenico, Jereczek-Fossa, Barbara A, Krengli, Marco, Garibaldi, Elisabetta, Tessa, Maria, Moro, Gregorio, Girelli, Giuseppe, Gabriele, Pietro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4765202/
https://www.ncbi.nlm.nih.gov/pubmed/26911291
http://dx.doi.org/10.1186/s13014-016-0599-5
_version_ 1782417518113062912
author Gabriele, Domenico
Jereczek-Fossa, Barbara A
Krengli, Marco
Garibaldi, Elisabetta
Tessa, Maria
Moro, Gregorio
Girelli, Giuseppe
Gabriele, Pietro
author_facet Gabriele, Domenico
Jereczek-Fossa, Barbara A
Krengli, Marco
Garibaldi, Elisabetta
Tessa, Maria
Moro, Gregorio
Girelli, Giuseppe
Gabriele, Pietro
author_sort Gabriele, Domenico
collection PubMed
description BACKGROUND: The aim of this work is to develop an algorithm to predict recurrence in prostate cancer patients treated with radical radiotherapy, getting up to a prognostic power higher than traditional D’Amico risk classification. METHODS: Two thousand four hundred ninety-three men belonging to the EUREKA-2 retrospective multi-centric database on prostate cancer and treated with external-beam radiotherapy as primary treatment comprised the study population. A Cox regression time to PSA failure analysis was performed in univariate and multivariate settings, evaluating the predictive ability of age, pre-treatment PSA, clinical-radiological staging, Gleason score and percentage of positive cores at biopsy (%PC). The accuracy of this model was checked with bootstrapping statistics. Subgroups for all the variables’ combinations were combined to classify patients into five different “Candiolo” risk-classes for biochemical Progression Free Survival (bPFS); thereafter, they were also applied to clinical PFS (cPFS), systemic PFS (sPFS) and Prostate Cancer Specific Survival (PCSS), and compared to D’Amico risk grouping performances. RESULTS: The Candiolo classifier splits patients in 5 risk-groups with the following 10-years bPFS, cPFS, sPFS and PCSS: for very-low-risk 90 %, 94 %, 100 % and 100 %; for low-risk 74 %, 88 %, 94 % and 98 %; for intermediate-risk 60 %, 82 %, 91 % and 92 %; for high-risk 43 %, 55 %, 80 % and 89 % and for very-high-risk 14 %, 38 %, 56 % and 70 %. Our classifier outperforms D’Amico risk classes for all the end-points evaluated, with concordance indexes of 71.5 %, 75.5 %, 80 % and 80.5 % versus 63 %, 65.5 %, 69.5 % and 69 %, respectively. CONCLUSIONS: Our classification tool, combining five clinical and easily available parameters, seems to better stratify patients in predicting prostate cancer recurrence after radiotherapy compared to the traditional D’Amico risk classes. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13014-016-0599-5) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4765202
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-47652022016-02-25 Beyond D’Amico risk classes for predicting recurrence after external beam radiotherapy for prostate cancer: the Candiolo classifier Gabriele, Domenico Jereczek-Fossa, Barbara A Krengli, Marco Garibaldi, Elisabetta Tessa, Maria Moro, Gregorio Girelli, Giuseppe Gabriele, Pietro Radiat Oncol Research BACKGROUND: The aim of this work is to develop an algorithm to predict recurrence in prostate cancer patients treated with radical radiotherapy, getting up to a prognostic power higher than traditional D’Amico risk classification. METHODS: Two thousand four hundred ninety-three men belonging to the EUREKA-2 retrospective multi-centric database on prostate cancer and treated with external-beam radiotherapy as primary treatment comprised the study population. A Cox regression time to PSA failure analysis was performed in univariate and multivariate settings, evaluating the predictive ability of age, pre-treatment PSA, clinical-radiological staging, Gleason score and percentage of positive cores at biopsy (%PC). The accuracy of this model was checked with bootstrapping statistics. Subgroups for all the variables’ combinations were combined to classify patients into five different “Candiolo” risk-classes for biochemical Progression Free Survival (bPFS); thereafter, they were also applied to clinical PFS (cPFS), systemic PFS (sPFS) and Prostate Cancer Specific Survival (PCSS), and compared to D’Amico risk grouping performances. RESULTS: The Candiolo classifier splits patients in 5 risk-groups with the following 10-years bPFS, cPFS, sPFS and PCSS: for very-low-risk 90 %, 94 %, 100 % and 100 %; for low-risk 74 %, 88 %, 94 % and 98 %; for intermediate-risk 60 %, 82 %, 91 % and 92 %; for high-risk 43 %, 55 %, 80 % and 89 % and for very-high-risk 14 %, 38 %, 56 % and 70 %. Our classifier outperforms D’Amico risk classes for all the end-points evaluated, with concordance indexes of 71.5 %, 75.5 %, 80 % and 80.5 % versus 63 %, 65.5 %, 69.5 % and 69 %, respectively. CONCLUSIONS: Our classification tool, combining five clinical and easily available parameters, seems to better stratify patients in predicting prostate cancer recurrence after radiotherapy compared to the traditional D’Amico risk classes. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13014-016-0599-5) contains supplementary material, which is available to authorized users. BioMed Central 2016-02-24 /pmc/articles/PMC4765202/ /pubmed/26911291 http://dx.doi.org/10.1186/s13014-016-0599-5 Text en © Gabriele et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Gabriele, Domenico
Jereczek-Fossa, Barbara A
Krengli, Marco
Garibaldi, Elisabetta
Tessa, Maria
Moro, Gregorio
Girelli, Giuseppe
Gabriele, Pietro
Beyond D’Amico risk classes for predicting recurrence after external beam radiotherapy for prostate cancer: the Candiolo classifier
title Beyond D’Amico risk classes for predicting recurrence after external beam radiotherapy for prostate cancer: the Candiolo classifier
title_full Beyond D’Amico risk classes for predicting recurrence after external beam radiotherapy for prostate cancer: the Candiolo classifier
title_fullStr Beyond D’Amico risk classes for predicting recurrence after external beam radiotherapy for prostate cancer: the Candiolo classifier
title_full_unstemmed Beyond D’Amico risk classes for predicting recurrence after external beam radiotherapy for prostate cancer: the Candiolo classifier
title_short Beyond D’Amico risk classes for predicting recurrence after external beam radiotherapy for prostate cancer: the Candiolo classifier
title_sort beyond d’amico risk classes for predicting recurrence after external beam radiotherapy for prostate cancer: the candiolo classifier
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4765202/
https://www.ncbi.nlm.nih.gov/pubmed/26911291
http://dx.doi.org/10.1186/s13014-016-0599-5
work_keys_str_mv AT gabrieledomenico beyonddamicoriskclassesforpredictingrecurrenceafterexternalbeamradiotherapyforprostatecancerthecandioloclassifier
AT jereczekfossabarbaraa beyonddamicoriskclassesforpredictingrecurrenceafterexternalbeamradiotherapyforprostatecancerthecandioloclassifier
AT krenglimarco beyonddamicoriskclassesforpredictingrecurrenceafterexternalbeamradiotherapyforprostatecancerthecandioloclassifier
AT garibaldielisabetta beyonddamicoriskclassesforpredictingrecurrenceafterexternalbeamradiotherapyforprostatecancerthecandioloclassifier
AT tessamaria beyonddamicoriskclassesforpredictingrecurrenceafterexternalbeamradiotherapyforprostatecancerthecandioloclassifier
AT morogregorio beyonddamicoriskclassesforpredictingrecurrenceafterexternalbeamradiotherapyforprostatecancerthecandioloclassifier
AT girelligiuseppe beyonddamicoriskclassesforpredictingrecurrenceafterexternalbeamradiotherapyforprostatecancerthecandioloclassifier
AT gabrielepietro beyonddamicoriskclassesforpredictingrecurrenceafterexternalbeamradiotherapyforprostatecancerthecandioloclassifier
AT beyonddamicoriskclassesforpredictingrecurrenceafterexternalbeamradiotherapyforprostatecancerthecandioloclassifier